{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T04:10:26Z","timestamp":1717215026082},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,6,1]]},"DOI":"10.2169\/internalmedicine.2307-23","type":"journal-article","created":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T22:15:51Z","timestamp":1699827351000},"page":"1585-1590","source":"Crossref","is-referenced-by-count":0,"title":["Macitentan Administration for Pulmonary Hypertension Due to \u03b2-thalassemia with Multiple Organ Failure"],"prefix":"10.2169","volume":"63","author":[{"given":"Kento","family":"Takagi","sequence":"first","affiliation":[{"name":"Department of Respirology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Kasai","sequence":"additional","affiliation":[{"name":"Department of Respirology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tani","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichiro","family":"Sakao","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, School of Medicine, International University of Health and Welfare (IUHW), Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Sugiura","sequence":"additional","affiliation":[{"name":"Department of Respirology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Respirology, Graduate School of Medicine, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Taher AT, Musallam KM, Cappellini MD. \u03b2-thalassemias. N Engl J Med 384: 727-743, 2021.","DOI":"10.1056\/NEJMra2021838"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Derchi G, Galanello R, Bina P, et al. Prevalence and risk factors for pulmonary arterial hypertension in a large group of \u03b2-thalassemia patients using right heart catheterization: a Webthal study. Circulation 129: 338-345, 2014.","DOI":"10.1161\/CIRCULATIONAHA.113.002124"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Fraidenburg DR, Machado RF. Pulmonary hypertension associated with thalassemia syndromes. Ann N Y Acad Sci 1368: 127-139, 2016.","DOI":"10.1111\/nyas.13037"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wood JC. Pulmonary hypertension in thalassemia: a call to action. Blood 139: 1937-1938, 2022.","DOI":"10.1182\/blood.2021015340"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Atichartakarn V, Chuncharunee S, Chandanamattha P, Likittanasombat K, Aryurachai K. Correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusion in an asplenic hemoglobin E\/\u03b2-thalassemia patient. Blood 103: 2844-2846, 2004.","DOI":"10.1182\/blood-2003-09-3094"},{"key":"6","unstructured":"6. Derchi G, Forni GL, Formisano F, et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica 90: 452-458, 2005."},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Morris CR, Kim HY, Wood J, et al. Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica 98: 1359-1367, 2013.","DOI":"10.3324\/haematol.2012.082065"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Jalalian R, Moghadamnia AA, Tamaddoni A, Khafri S, Iranian M. Comparing the efficacy of tadalafil versus placebo on pulmonary artery systolic pressure and right ventricular function in patients with beta-thalassaemia intermedia. Heart Lung Circ 26: 677-683, 2017.","DOI":"10.1016\/j.hlc.2016.11.003"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Karami H, Darvishi-Khezri H, Kosaryan M, Akbarzadeh R, Dabirian M. The improvement of pulmonary artery pressure after bosentan therapy in patients with \u03b2-thalassemia and Doppler-defined pulmonary arterial hypertension. Int Med Case Rep J 12: 1-7, 2018.","DOI":"10.2147\/IMCRJ.S180602"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Anthi A, Tsangaris I, Hamodraka ES, Lekakis J, Armaganidis A, Orfanos SE. Treatment with bosentan in a patient with thalassemia intermedia and pulmonary arterial hypertension. Blood 120: 1531-1532, 2012.","DOI":"10.1182\/blood-2012-04-422568"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Anthi A, Tsiapras D, Karyofyllis P, Voudris V, Armaganidis A, Orfanos SE. The wide spectrum of \u03b2-thalassaemia intermedia-induced pulmonary hypertension: two case reports on the possible role of specific pulmonary arterial hypertension therapy. Pulm Circ 11: 1-4, 2021.","DOI":"10.1177\/20458940211030490"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ussavarungsi K, Burger CD. Pulmonary arterial hypertension in a patient with \u03b2-thalassemia intermedia and reversal with infusion epoprostenol then transition to oral calcium channel blocker therapy: review of literature. Pulm Circ 4: 520-526, 2014.","DOI":"10.1086\/677367"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Correale M, Zicchino S, Monaco I, Brunetti ND, Di Biase M. Association therapy with macitentan added to sildenafil in a thalassemic patient with pulmonary hypertension. Int J Cardiol 220: 80-81, 2016.","DOI":"10.1016\/j.ijcard.2016.06.133"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Barst RJ, Mubarak KK, Machado RF, et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol 149: 426-435, 2010.","DOI":"10.1111\/j.1365-2141.2010.08097.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Wei A, Gu Z, Li J, et al. Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials. J Am Heart Assoc 5: e003896, 2016.","DOI":"10.1161\/JAHA.116.003896"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369: 809-818, 2013.","DOI":"10.1056\/NEJMoa1213917"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sidharta PN, Lindegger N, Ulc I, Dingemanse J. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment. J Clin Pharmacol 54: 291-300, 2014.","DOI":"10.1002\/jcph.193"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol 53: 21S-30S, 2002.","DOI":"10.1046\/j.0306-5251.2001.00029.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Forgue ST, Phillips DL, Bedding AW, et al. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. Br J Clin Pharmacol 63: 24-35, 2007.","DOI":"10.1111\/j.1365-2125.2006.02726.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Frey R, Becker C, Unger S, Schmidt A, Wensing G, M\u00fcck W. Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulm Circ 6: S5-S14, 2016.","DOI":"10.1086\/685015"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/11\/63_2307-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T03:34:59Z","timestamp":1717212899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/11\/63_2307-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2307-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,1]]},"article-number":"2307-23"}}